Marks key milestone as Evommune’s first clinical program which should allow EVO101 to rapidly advance into Phase 2a.
Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being developed as a treatment for inflammatory skin diseases.
« We are excited to enroll the first participant into a clinical study of EVO101, the first of several programs in our pipeline approaching clinical development, » said Eugene A. Bauer, M.D., chief medical officer of Evommune. « Given EVO101’s potent inhibitory activity, this compound has the potential to be a first-in-class treatment with significant efficacy across a broad spectrum of patients. Based on the results of this study, we expect to rapidly advance EVO101 into Phase 2a clinical trials in patients suffering from atopic dermatitis and rosacea. »
The open-label Phase 1 study will assess the safety and tolerability of EVO101 in healthy adult volunteers. Participants will apply EVO101 topical cream, 0.1% twice daily and be evaluated for adverse events and local skin responses over a 7-day period.